Tina Matlawski
A5027898036- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Advancements in Semiconductor Devices and Circuit Design
- Cancer Immunotherapy and Biomarkers
- Semiconductor materials and devices
- CRISPR and Genetic Engineering
- Nanowire Synthesis and Applications
- Viral Infectious Diseases and Gene Expression in Insects
- Cytomegalovirus and herpesvirus research
- RNA Interference and Gene Delivery
University of Pennsylvania
2019-2023
CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells fight cancer. We report first-in-human phase 1 clinical trial test safety and feasibility multiplex engineer in three patients with refractory Two genes encoding endogenous cell receptor (TCR) chains, TCRα (
Purpose: Treatments are limited for metastatic melanoma and triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting cell-surface cMET. Experimental Design: Metastatic or mTNBC subjects had at least 30% tumor expression cMET, measurable disease progression on prior therapy. Patients received up to six infusions (1 × 10e8 cells/dose) CAR without...
10035 Background: Advanced relapsed/refractory melanoma and metastatic triple-negative breast cancer are lethal diseases for which effective therapies limited. We conducted a pilot phase I clinical trial (NCT03060356) to establish the safety feasibility of intravenous autologous chimeric antigen receptor (CAR) T cell immunotherapy targeting cMET, cell-surface that is highly expressed in these cancers. Methods: Subjects had or unresectable (Mel) (BC) with ≥30% expression cMET on archival...
<h3>Background</h3> Most women with epithelial ovarian cancer develop uniformly incurable disease recurrence. Chimeric antigen receptor (CAR) T cells pair the MHC-independent tumor-recognition capabilities of monoclonal antibodies cytotoxicity effector cells. The success CAR cell therapy in solid tumors has been hindered by (1) difficulty identifying highly expressed, tumor-specific, surface target antigens; (2) limited trafficking and infiltration; (3) suboptimal cytotoxic activity. Alpha...
<p>Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 prior to infusion and B at the time of post-infusion biopsy.</p>
<p>Supplementary Figure 1. : Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 prior to infusion; B: at post-infusion biopsy; C: Ki-67 D: biopsy.</p>
<div>Abstract<p>Purpose: Treatments are limited for metastatic melanoma (MM) and triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety feasibility of intravenous RNA- electroporated chimeric antigen receptor (CAR) T cells targeting cell-surface cMET. Patients Methods: MM or mTNBC subjects had at least 30% tumor expression cMET, measurable disease progression on prior therapy. received up to 6 infusions (1x10e8 / dose) CAR without...
<p>Supplementary Figure 1. : Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 prior to infusion; B: at post-infusion biopsy; C: Ki-67 D: biopsy.</p>
<p>Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 prior to infusion and B at the time of post-infusion biopsy.</p>
<p>Response</p>
<p>Study procedures. Participant study procedures including cell collection/manufacturing timeline as well infusion schedule from eligibility confirmation onward.</p>
<p>Patient population</p>
<p>mRNA signals corresponding to CAR T cells in peripheral blood</p>
<p>Supplementary Figure 2: Representative immunohistochemical staining for Subject 27 with metastatic triple-negative breast cancer; lymph node biopsy. Panel A shows CD8 prior to infusion and B at the time of post-infusion biopsy.</p>
<p>Supplementary Figure 1.: Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 prior to infusion; B: at post-infusion biopsy; C: Ki-67 D: biopsy.</p>
<div>Purpose:<p>Treatments are limited for metastatic melanoma and triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting cell-surface cMET.</p>Experimental Design:<p>Metastatic or mTNBC subjects had at least 30% tumor expression cMET, measurable disease progression on prior therapy. Patients received up to six infusions (1 × 10e8...
<p>Response</p>
<p>IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had tissue available for analysis; demonstrated an increase cytoxic CD8<sup>+</sup> cells all 3 subjects.</p>
<p>Supplementary Figure 1.: Representative immunohistochemical staining for Subject 74 with metastatic melanoma; lymph node biopsy. Panel A: pS6 prior to infusion; B: at post-infusion biopsy; C: Ki-67 D: biopsy.</p>
<p>IHC analysis of CD8 in preinfusion and postinfusion tumor tissue. Three subjects had tissue available for analysis; demonstrated an increase cytoxic CD8<sup>+</sup> cells all 3 subjects.</p>
<p>IHC analysis of paired tumor tissue</p>
<p>Adverse events, clinically relevant (# subjects includes those with the given toxicity at least possibly related to study treatment)</p>
<p>Study procedures. Participant study procedures including cell collection/manufacturing timeline as well infusion schedule from eligibility confirmation onward.</p>